The explosion of GLP-1 weight loss drugs is reminiscent of the early days of PD-1 inhibitors, but key market differences ...

There are early and suggestive data that GLP-1 drugs reduce alcohol cravings. A large cohort of people with alcohol use ...

Depression risk for patients receiving GLP-1 RA was slightly higher than those receiving SGLT-2i and lower than those receiving DPP-4i.

With respect to risks, GLP-1RA use was significantly associated with an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, drug-induced pancreatitis, and other ...

Tom Nolan reviews this week’s research Is it time to treat male partners of women with bacterial vaginosis? A trial in the New England Journal of Medicine recruited women with confirmed bacterial ...

As obesity drug developers compete for the highest weight-loss efficacy, experts contend that overall health ...

Over 13 weeks, adults with type 2 diabetes using an automated insulin delivery (AID) system had a 0.6-percentage point ...

The use of GLP-1 receptor agonists, like semaglutide, to treat type 2 diabetes is not associated with an increased risk of ...

With increasing demand and higher costs, ensuring appropriate patient access is more critical than ever and 2025 will likely ...

SGLT2 inhibitors were associated with better cardioprotective effects among older adults than younger adults with type 2 diabetes.

Investigators evaluated dipeptidyl peptidase 4 (DPP4) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, and SGLT2 inhibitors to determine if differences in efficacy are associated ...